Pharma Industry Readies for Drug Pricing Lawsuit Second Wave (1)

Major drug companies are likely to ratchet up a sprawling legal attack aimed at challenging the Biden administration’s Medicare drug pricing negotiation process, a top pharmaceutical lobby leader told Bloomberg Law.

“There is likely to be a second wave” of lawsuits against the Biden administration’s Health and Human Services Department over Medicare drug pricing negotiations, Pharmaceutical Research and Manufacturers of America (PhRMA) CEO Stephen Ubl told Bloomberg Law reporters Tuesday.

The HHS is facing nine lawsuits over the drug price negotiation program, filed by Merck & Co., Bristol-Myers Squibb Co., other drugmakers, and industry groups. PhRMA is among ...